肺泡表面活性物质对早产儿呼吸窘迫综合征患儿水通道蛋白和氧合水平的影响  

Effects of alveolar surface active substances on aquaporins and oxygenation levels in premature infants with respiratory distress syndrome

作　　者：沙得哈西 丁效国[1] 黄艳[1] 杨丽[1] Shadehaxi;DING Xiaoguo;HUANG Yan;YANG Li(Department of Pediatrics,Hospital of Xinjiang Production and Construction Corps,Urumqi,Xinjiang,830002,China)

机构地区：[1]新疆生产建设兵团医院儿科

出　　处：《新疆医学》2019年第6期566-569,共4页Xinjiang Medical Journal

基　　金：新疆生产建设兵团医院院级科研项目（项目编号：LC2014006）;新疆兵团科技计划项目（项目编号：2013BA017）

摘　　要：目的分析肺泡表面活性物质对早产儿呼吸窘迫综合征患儿水通道蛋白和氧合水平的影响。方法选取本院(2013年3月-2018年9月)收治的早产儿呼吸窘迫综合征患儿37例,根据治疗方法不同分为对照组(常规治疗)和观察组(常规治疗+肺表面活性物质治疗),分析两组患者治疗后的临床效果。结果观察组患儿显效14例、有效3例、总有效率为89.47%,对照组显效9例、有效3例、总有效率为66.67%,观察组患儿总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患儿转化生长因子-β1(TGF-β1)、肿瘤坏死因子-α(TNF-α)、水通道蛋白-1(AQP-1)、水通道蛋白-5(AQP-5)水平及血气指标比较,差异无统计学意义(P>0.05)。治疗后,观察组患儿TGF-β1、TNF-α、水通道蛋白水平低于对照组,血气指标优于对照组,差异有统计学意义(P<0.05)。观察组患儿不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论肺泡表面活性物质治疗早产儿呼吸窘迫综合征疗效显著,可改善肺的氧合功能,降低水通道蛋白、TGF-β1、TNF-α水平,且安全性高。Objective To analyze the effects of alveolar surface active substances on aquaporins and oxygenation levels in premature infants with respiratory distress syndrome.Methods FromMarch 2013 to September 2018,37 cases of premature infants with respiratory distress syndrome were selected.According to the treatment methods,the patients were divided into two groups:control group(routine treatment)and observation group(routine treatment of pulmonary surfactant).Results There were 14 cases with marked effect,3 cases had effect.Total effective rate in the observation group was 89.47%of.There were 9 cases with obvious effect in the control group,and 3 cases had effect.Total effective rate in the control group was 66.67%.The total effective rate of the observation group was higher than that of the control group(P<0.05).Before treatment,the levels of transforming growth factor-β1(TGF-β1),tumor necrosis factor-α(TNF-α),aquaporin-1(AQP-1),aquaporin-5(AQP-5)and blood gas were not significantly different between the two groups(P>0.05).After treatment,the levels of TGF-β1 TNF-αand aquaporin in the observation group were lower than those in the control group,and the blood gas index was better than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Pulmonary surfactant was effective in the treatment of respiratory distress syndrome of premature infants.It could improve lung oxygenation function,reduce aquaporin,TGF-β1 and TNF-αlevel,and had high safety.

关 键 词：肺泡表面活性物质 早产儿 呼吸窘迫综合征 水通道蛋白 

分 类 号：R453.9[医药卫生—治疗学]